Association of plasma homocysteine with serum interleukin-6 and C-peptide levels in patients with type 2 diabetes

Hyperhomocysteinemia is an independent risk factor for atherosclerotic disease. Because serum markers of inflammation and the metabolic syndrome are also associated with atherosclerotic disease and insulin resistance, we investigated whether plasma homocysteine (Hcy) levels were associated with serum markers of inflammation and factors of metabolic syndrome in 223 elderly patients with type 2 diabetes mellitus. The levels of plasma Hcy and serum interleukin-6 (IL-6), high-sensitivity C-reactive protein, and C-peptide were measured. The C677T mutation of methylenetetrahydrofolate reductase (MTHFR) gene was detected using the polymerase chain reaction-restriction fragment length polymorphism method. The number of abnormal metabolic factors (presence of diabetes, blood pressure >= 130/85 mm Hg, triglycerides >= 150 mg/dL, high-density lipoprotein cholesterol < 35 mg/dL (men) or < 39 mg/dL (women), or body mass index > 25 kg/m(2)) was assessed. Elevated plasma Hey levels correlated significantly with serum IL-6 (r = 0.25, P < .001), C-peptide (r = 0.22, P < .0 1), and the number of abnormal metabolic factors (r = 0.20, P < .01), but not with C-reactive protein. Multiple linear regression analysis revealed that log-transformed IL-6, serum C-peptide. vitamin B-12, and creatinine were significant determinants of plasma Hcy levels. The correlation between Hcy and IL-6 levels was strongest in those with TT genotype of C677T MTHFR among 3 genotypes. The association between plasma Hcy and serum IL-6 levels supports the hypothesis that the activation of innate immunity is involved in the pathogenesis of arteriosclerosis in patients with diabetes mellitus who are homozygous for the TT genotype of C677T MTHFR. (c) 2005 Elsevier Inc. All rights reserved.